# **Cue Biopharma, Inc.** Q2 Earnings & Business Update






### **Forward-Looking Statements Disclaimer**

This presentation has been prepared by Cue Biopharma, Inc. ("we," "us," "our," "Cue" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither this presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future, "vision", "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this presentation regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding our development plans for CUE-101 and the continued buildout of our pipeline, the sufficiency of our cash, cash equivalents and marketable securities to support the clinical development of CUE-101, anticipated results of our drug development efforts, including study results, our expectations regarding the timing of milestone events, regulatory developments and expected future operating results. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, our limited operating history, limited cash and a history of losses; our ability to achieve profitability; potential setbacks in our research and development efforts including negative or inconclusive results from our preclinical studies, our ability to secure required U.S. Food and Drug Administration ("FDA") or other governmental approvals for our product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on our operations and clinical trials; negative or inconclusive results from our clinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in our clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; our reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; our ability to obtain adequate financing to fund our business operations in the future; our ability to maintain and enforce necessary patent and other intellectual property protection, competitive factors, general economic and market conditions; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by us in this presentation is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.



### Immuno-STATs: Pipeline for Restoration of Immune Balance



- CUE-100 series (IL-2 targeted to tumor-specific T cells)
  - CUE-101 (HPV-E7) (R/M HNSCC)
    - Efficacy: > doubling of ORR & mPFS vs SoC
    - Alignment with FDA on a registration path
  - CUE-102 (Wilms' Tumor-1, WT-1) (Ova., CRC, Gastric, Pancr.)
    - > Ph 1a monotherapy dose escalation completed
    - Evidence of anti-tumor activity in several patients
  - Pre-clinical pipeline of Immuno-STATs targeting KRAS (G12D/V), MAGE-A4, MART-1, NY-ESO1, PRAME, etc.


- CUE-401 (Regulatory T cells, Tregs)
  - Biologic for conversion and expansion of <u>new</u> Tregs
  - Broad applications in autoimmune and inflammatory diseases
  - Partnered with Ono Pharmaceuticals (option for 50% US rights)

#### CUE-500 Series (targeting autoreactive B cells)

- MoA: T cell-mediated B cell depletion
- Potential for a biologic to achieve "CAR-T-like" efficacy
- Broad applications in many autoimmune diseases




### **CUE-401:** IL-2/TGF-β Bispecific for Treg Conversion and Expansion




UE Ono Pharmaceutical funding ongoir Cue retains a 50% co-development


### **CUE-401:** Differentiated MoA and In Vivo Efficacy



**CUE-401 MoA:** Treg differentiation requires both IL-2 and TGF-β signals




Short-term treatment with CUE-401 results in significant long-term protection from gastritis and tissue destruction



Source: Sponsored Research Collaboration with Dr. Richard DiPaolo, St. Louis University


### **CUE-500 Series:** Selective T Cell Engagers for B Cell Depletion



Selective Engagement of Virus-

#### Advantages of VSTs over other T cells:

- ✓ Trained memory killer T cells
- ✓ Present in high frequency in peripheral (diseased) tissue<sup>1,2,3,4</sup>
- ✓ Rapid serial killing function
- ✓ Avoids broad immune activation
- ✓ No x-reactivity towards self-tissue
  - 1. Poon et al., Cell Rep. 2021 Nov 30;37(9):110071
  - 2. Tan et al., Arth. Res. 2000
  - 3. Scotetetal, Eur. Jour. Imm 1999
  - 4. Turcinov et al., Arth. Rheum. 2023




*Note:* CUE-500 series leverages a derisked, validated framework via the oncology clinical experience



### **CUE-501:** Potent and Selective B Cell Killing


CUE-501 selectively redirects CMV-specific memory CD8+ T cells to kill human B cells



- anti-CD19/CD3 Bispecific



# **CUE-501 vs. Bispecific Pan T Cell Engagers:** Significant Reduction in Cytokine Release



CUE-501 redirects CMV-specific memory CD8+ T cells to kill human B cells with reduced cytokine production relative to anti-CD3/CD19 bispecific




### **CUE-500 Series:** Significant Superior Differentiation

	CAR-T Cell Therapy	Pan TCE Molecules (e.g., anti-CD3/CD19)	CUE-500 TCE
Selective activation of trained virus-specific killer T cells ("effector VST cells")	X	X	$\checkmark$
Takes advantage of effector VST cells present in circulation and diseased tissue	X	X	$\checkmark$
Avoid broad/systemic immune activation (CRS, ICANS, other toxicities, including self-reactivity)	X	X	$\checkmark$
Off-the-shelf administration and amenable to sub- cutaneous dosing	X	$\checkmark$	$\checkmark$
Avoid patient pre-conditioning regimens and enable out-patient administration	X	$\checkmark$	$\checkmark$
Manufacturing and supply chain	Complex	Standard biologic	Standard biologic



### **CUE-101 + Keytruda in 1L HPV+ R/M HNSCC – Key Differentiation:** Enhanced Clinical Benefit in Patients with CPS ≥1






Includes 24/25 patients in Response Evaluable Population. CFB = Change from baseline in sum of diameters of target lesions.

10

# Substantial Enhancement of PFS and Marked Increase in OS in 1L R/M HNSCC (CPS ≥ 1)

**Progression Free Survival 4 mg/kg Combination Therapy** 




**Overall Survival 4 mg/kg Combination Therapy** 

Data Extract: 04-Aug-24 from live database with active patients.



Probability of PFS

### **CUE-101 4 mg/kg + Pembrolizumab in 1L R/M HNSCC:** Marked Increase in Survival in CPS-low and CPS-high Patients




	PD-L1 CPS 1-19		PD-L1 CPS ≥ 20	
	Pembro Mono <sup>1</sup>	CUE-101 + Pembro	Pembro Mono <sup>1</sup>	CUE-101 + Pembro
Median OS (months)	10.8	21.8	14.8	Undefined
12-Month OS rate	44%	82%	56%	100%



1. Burtness JCO 2022

D 2022 Data Extract: 04-Aug-24 from live database with active patients.

### CUE-101 Monotherapy in 2L+ R/M HNSCC: Notable Increase in Survival Observed at 2 and 4 mg/kg



1. Ferris et al Checkmate 141 NEJM 375;19, 2016

2. Cohen et al KEYNOTE-040 Lancet, 2018



CUE-101 Median Overall Survival

## Mission

### Translating "Nature's Cues" into breakthrough immunotherapies

- Goal of establishing new standards of care for unmet needs in oncology and autoimmunity with potential for large market opportunities
- Clinically validated oncology programs with potential "best-in-class" T cell engagers demonstrate favorable tolerability and efficacy:
  - Provides significant risk reduction for entire Immuno-STAT<sup>™</sup> platform
  - Clinical data continuing to mature
- Advancing preclinical autoimmune programs to target multiple diseases with potential for significant value creation:
  - **CUE-401:** Unique bispecific for induction & expansion of regulatory T cells Partnered with Ono Pharmaceutical (*Cue Biopharma has option to co-develop in U.S.*)
  - **CUE-501:** Novel biologic for B cell depletion in autoimmune diseases
- Implementing business model to mitigate capital access risk via partnerships for sustainable shareholder value potential

## Thank you

Translating "Nature's Cues" into breakthrough immunotherapies

